INKT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IN

Mkt Cap

$48.4M

Volume

13.46K

Next Earnings

November 13th

Loading chart

IN

INKTMiNK Therapeutics, Inc. Common Stock

INKT

Pay with—

Available Balance0.00

IN

Mkt Cap

$48.0M

Volume

13.46K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyGT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.Benzinga · Jun 2, 2026

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal CancerMiNK Therapeutics announced Phase II trial results for agenT-797 combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer. The study achieved a 77% disease control rate with long-term survival beyond 20 months in a subset of patients. An induction treatment strategy showed significant improvements in progression-free survival (6.9 vs. 3.5 months) and overall survival (9.5 vs. 5.2 months), though the trial did not meet its primary endpoint of objective response rate.GlobeNewswire Inc. · Apr 17, 2026

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026MiNK Therapeutics announced that Phase II trial data from Memorial Sloan Kettering Cancer Center evaluating agenT-797 (an allogeneic iNKT cell therapy) combined with botensilimab and balstilimab in PD-1 refractory gastroesophageal cancer will be presented at AACR 2026. The study represents one of the first clinical evaluations of iNKT cell therapy combined with dual checkpoint modulation in this indication, addressing an area of high unmet medical need.GlobeNewswire Inc. · Apr 3, 2026

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone SymposiaMiNK Therapeutics presented translational data at Keystone Symposia demonstrating significant depletion of iNKT cells in lung tissue from advanced IPF patients, supporting the mechanistic rationale for iNKT cell replenishment as a potential therapeutic approach. The findings expand MiNK's iNKT platform into chronic fibrotic lung disease, addressing a large unmet medical need affecting approximately 100,000 U.S. patients with limited treatment options.GlobeNewswire Inc. · Feb 4, 2026

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025MiNK Therapeutics presented clinical results showing promising immune cell therapy agenT-797 demonstrated durable responses and immune reactivation in patients with checkpoint-resistant solid tumors, with some patients experiencing complete remission lasting over two years.GlobeNewswire Inc. · Nov 7, 2025

MiNK Therapeutics Cuts Q2 Cash Use 31%MiNK Therapeutics reported a Q2 2025 net loss of $1.06 per share, with no revenue but promising clinical progress in iNKT cell therapies for cancer and immune diseases. The company raised $13 million in equity and continues advancing its lead product agenT-797 in clinical trials.The Motley Fool · Aug 14, 2025

MiNK Therapeutics Announces Virtual Annual Shareholders MeetingMiNK Therapeutics, a clinical-stage biopharmaceutical company, announced its upcoming virtual Annual Shareholders Meeting and provided updates on its pipeline, including a NIAID grant for its allogeneic iNKT cell therapy for stem cell transplant patients and positive clinical data in various cancer indications.GlobeNewswire Inc. · Jun 10, 2025

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual MeetingMiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that it will present interim data from its ongoing Phase 2 study testing AgenT-797 in combination with Agenus' botensilimab and balstilimab in patients with refractory gastric cancer.GlobeNewswire Inc. · Feb 12, 2025

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GIMiNK Therapeutics presented data on a Phase 2 trial evaluating a combination of its iNKT cell therapy, Agenus' botensilimab and balstilimab, and standard chemotherapy in advanced gastroesophageal cancer patients. The novel combination demonstrated signals of tolerability and activity in this patient population.GlobeNewswire Inc. · Jan 23, 2025

MiNK Therapeutics Announces Virtual Annual Shareholders MeetingNEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.GlobeNewswire Inc. · Jun 5, 2024

to start trading

IN

INKTMiNK Therapeutics, Inc. Common Stock

INKT

Pay with—

Available Balance0.00

Your PositionYou don't own any INKT yet.

Related Tickers

Earnings